Phenotypic screening in cancer drug discovery — past, present and future
The DOI matches its Crossref record; 181 of the 182 references it cites were found in a registry or an index.
Abstract
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phenotypic screening is a strategy that analyzes biology-associated (phenotypic) effects in given models such as animals, cells, or organisms to help identify the targets of candidate drugs.25,50”
From Drug repurposing for cancer therapy (2024) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Cited by
Items 101–200 of 523
An overview of microtubule targeting agents for cancer therapy
Karahalıl, B., Yardım-Akaydin, S., & Baytaş, S. N. (2019) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/aiht-2019-70-3258 · Cited by 55
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 60
Nagasawa, I., Muroi, M., Kawatani, M., Ohishi, T., Ohba, S., Kawada, M., & Osada, H. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.010 · Cited by 56
Current advances in ligand‐based target prediction
Yang, S., Ye, Q., Ding, J., Yin, M., Lü, A., Chen, X., Hou, T., & Cao, D. (2020) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1504 · Cited by 61
Chemoproteomics, A Broad Avenue to Target Deconvolution
Gao, Y., Ma, M., Li, W., & Lei, X. (2023) · Advanced Science · doi:10.1002/advs.202305608 · Cited by 60
Sandercock, A. M., Rust, S., Guillard, S., Sachsenmeier, K. F., Holoweckyj, N., Hay, C., Flynn, M., Huang, Q., Yan, K., Herpers, B., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0415-0 · Cited by 53
“More subtle analyses have shown that therapeutics are often discovered by combining phenotypic and target-led screens, but that an initial phenotypic screen can be an effective way to identify initial leads [34].”
BackgroundArtificial intelligence for high content imaging in drug discovery
Puigvert, J. C., & Spjuth, O. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102842 · Cited by 57
“Single marker HCI, a traditional method of using a single dye, antibody or fluorophore to label and visualize a specific target or component within a sample, is a pivotal technique in cellular biology and drug discovery [42].”
MethodAdvances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models
Ziemba, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211202 · Cited by 64
“Phenotypic profiling has therefore transformed cytotoxicity assessment from a descriptive measure of cell death into a mechanistic discipline at the interface of cell biology, cheminformatics, and predictive toxicology [68].”
Zhang, Z., Chen, Y., Urs, S., Chen, L., Simeone, D. M., & Yoon, E. (2018) · Small · doi:10.1002/smll.201703617 · Cited by 55
Chow, M. J., Alfiean, M., Pastorin, G., Gaiddon, C., & Ang, W. H. (2017) · Chemical Science · doi:10.1039/c7sc00497d · Cited by 52
The resurgence of phenotypic screening in drug discovery and development
Wagner, B. K. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1122589 · Cited by 53
“Between 1999 and 2013, 31 of the 48 oncology NMEs were discovered by target-based approaches, and 21 of those NMEs were kinase inhibitors.[3] The paucity of historic phenotypic discoveries is”
BackgroundOpportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research
Brown, D. G., & Wobst, H. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00797 · Cited by 48
Stern, A. M., Schurdak, M. E., Bahar, İ., Berg, J. M., & Taylor, D. L. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116635818 · Cited by 50
“The next step involves the development of a phenotypic assay that can be one of two major types: (1) unbiased modulation of a specific pathway identified in the validation step(3) or (2) an unbiased modulation of a disease phenotype that may involve any or multiple pathways in which the goal is to modulate the disease…”
BackgroundJTE-607, a multiple cytokine production inhibitor, targets CPSF3 and inhibits pre-mRNA processing
Kakegawa, J., Sakane, N., Suzuki, K., & Yoshida, T. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.004 · Cited by 48
Next-Generation Phenotypic Screening
Warchal, S. J., Unciti-Broceta, A., & Carragher, N. O. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0025 · Cited by 43
Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease
Milenkovic, U., Ilg, M. M., Cellek, S., & Albersen, M. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.02.004 · Cited by 46
The Resurrection of Phenotypic Drug Discovery
Childers, W. E., Elokely, K. M., & Abou-Gharbia, M. A. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00006 · Cited by 48
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Recent Advances in Peptide-Based Approaches for Cancer Treatment
Conibear, A. C., Schmid, A., Kamalov, M., Becker, C. F. W., & Bello, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171123204851 · Cited by 45
Chen, S., Bi, K., Liang, H., Wu, Z., Huang, M., Chen, X. X., Dong, G., & Sheng, C. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.10.014 · Cited by 45
Suhito, I. R., Lee, W., Baek, S., Lee, D., Min, J., & Kim, T. P. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.03.031 · Cited by 43
Predictive models for estimating cytotoxicity on the basis of chemical structures
Sun, H., Wang, Y., Cheff, D. M., Hall, M. D., & Shen, M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115422 · Cited by 43
How many times should we screen a chemical library to discover an anticancer drug?
López‐Lázaro, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.006 · Cited by 46
Screening and identification of novel biologically active natural compounds
Newman, D. J. (2017) · F1000Research · doi:10.12688/f1000research.11221.1 · Cited by 41
Computational Methods for Single-Cell Imaging and Omics Data Integration
Watson, E. R., Fard, A. T., & Mar, J. C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.768106 · Cited by 49
“…2013), osteoarthritis (Nogueira-Recalde et al., 2019), Hutchinson – Gilford Progeria Syndrome (Kubben et al., 2016) and cancer (Caie et al., 2010; Moffat et al., 2014), as well as therapeutics for biological ageing as a whole (Sarkar et al., 2020), often through targeting cellular senescence…”
BackgroundAntiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 51
“215 218 These indicators can be singular, such as the cell survival rate, proliferation rate, and apoptosis rate, or they can be a combination of multiple indicators.”
Label-free target identification in drug discovery via phenotypic screening
Park, H., Ha, J., & Park, S. B. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.006 · Cited by 42
PRMT1 inhibition induces differentiation of colon cancer cells
Plotnikov, A. N., Kozer, N., Cohen, G., Carvalho, S., Duberstein, S., Almog, O., Solmesky, L. J., Shurrush, K. A., Babaev, I., Benjamin, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77028-8 · Cited by 45
Predicting cell morphological responses to perturbations using generative modeling
Palma, A., Theis, F. J., & Lotfollahi, M. (2025) · Nature Communications · doi:10.1038/s41467-024-55707-8 · Cited by 41
“The generated cellular responses can be used to narrow down the hypothesis space facilitating phenotype-based drug discovery [12].”
Li, Y., He, Y., Shao, T., Pei, H., Guo, W., Mi, D., Krimm, I., Zhang, Y., Wang, P., Wang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00059 · Cited by 39
Label-free target identification using in-gel fluorescence difference via thermal stability shift
Park, H., Ha, J., Koo, J. Y., Park, J., & Park, S. B. (2016) · Chemical Science · doi:10.1039/c6sc03238a · Cited by 40
The evolution of drug discovery: from phenotypes to targets, and back
Al‐Ali, H. (2016) · MedChemComm · doi:10.1039/c6md00129g · Cited by 46
Post-Ugi Cascade Transformations for Accessing Diverse Chromenopyrrole Collections
Srinivasulu, V., Sieburth, S. M., El‐Awady, R., Kariem, N. M., Tarazi, H., O’Connor, M. J., & Al‐Tel, T. H. (2018) · Organic Letters · doi:10.1021/acs.orglett.7b03986 · Cited by 37
Pei, Z. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102334 · Cited by 52
Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
Sant, G. R., Knopf, K., & Albala, D. M. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0025-y · Cited by 38
The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery
Friese, A., Ursu, A., Hochheimer, A., Schöler, H. R., Waldmann, H., & Bruder, J. M. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.05.007 · Cited by 37
Yin, X., Li, Q., Shu, Y., Wang, H., Thomas, B., Maxwell, J. T., & Zhang, Y. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01035-4 · Cited by 44
“This not only enhances efficiency but also increases the feasibility of drug discovery [82].”
BackgroundYu, J., Ahn, S.-Y., Kim, H. J., Lee, M. Y., Ahn, S., Kim, J., Jin, S. H., Lee, E., Kim, G., Cheong, J. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00805 · Cited by 35
Direct and indirect approaches to identify drug modes of action
Tulloch, L. B., Menzies, S. K., Coron, R. P., Roberts, M. D., Florence, G. J., & Smith, T. (2017) · IUBMB Life · doi:10.1002/iub.1697 · Cited by 39
“While there have undoubtedly been a large number of successes from target-based methods (11,13), attrition rates are high as lead compounds identified and optimized in vitro often fail in subsequent cell-based trials due to a range of issues including poor cell uptake, preferential off-target binding; unexpected toxic…”
BackgroundYou, W., Zhou, Z., Li, Z., Yan, J., & Wang, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101322 · Cited by 37
Overview of Research and Development for Anticancer Drugs
Xu, J., & Mao, W. (2016) · Journal of Cancer Therapy · doi:10.4236/jct.2016.710077 · Cited by 35
“At present, over 200 anticancer biopharmaeuticals have been approved, with many more at various stages of preclinical development, or clinical Phase I and II trials [2] [8] [9].”
BackgroundDiversity-Oriented Synthetic Strategies Applied to Cancer Chemical Biology and Drug Discovery
Collins, I., & Jones, A. M. (2014) · Molecules · doi:10.3390/molecules191117221 · Cited by 36
“Phenotypic screens in cancer have often been focussed on general and potentially non-specific endpoints, such as cytotoxicity or anti-proliferative effects, which can limit interpretation of the mode of action of hit compounds [20].”
BackgroundLuan, M., Yu, L., Li, Y., Pan, W., Gao, X., Wan, X., Li, N., & Tang, B. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03146 · Cited by 36
Integration of FRET and sequencing to engineer kinase biosensors from mammalian cell libraries
Liu, L., Limsakul, P., Meng, X., Huang, Y., Harrison, R. E. S., Huang, T.-S., Shi, Y., Yu, Y., Charupanit, K., Zhong, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25323-x · Cited by 34
Martina, M. G., Giorgio, C., Allodi, M., Palese, S., Barocelli, E., Ballabeni, V., Szpakowska, M., Chevigné, A., van Hamburg, J. P., Davelaar, N., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114703 · Cited by 34
Cheng, X., Xia, X., Ren, D., Chen, Q., Xu, G., Wei, F., Yang, J., Wang, L., Hu, Q., Zou, J., et al. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340748 · Cited by 33
Ye, X., Chan, K. C., Waters, A. M., Bess, M., Harned, A., Wei, B., Lončarek, J., Luke, B. T., Orsburn, B. C., Hollinger, B. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13566 · Cited by 35
“com/oncotarget screens are commonly used in the process of cancer drug discovery [23].”
BackgroundPhenotypic chemical biology for predicting safety and efficacy
Berg, E. L. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.01.001 · Cited by 35
Aldea, M. D., Michot, J., Danlos, F., Ribas, A., & Soria, J. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0144 · Cited by 35
“Beyond chemotherapy, new drugs such as targeted therapy, immunotherapy, epigenetic modifiers, and more recently cellular therapies have been approved and have succeeded in improving lifetime expectancy and quality of life of patients living with cancer (2).”
BackgroundAffinity purification in target identification: the specificity challenge
Zheng, W., Li, G., & Li, X. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0635-2 · Cited by 34
“…Laboratory of Bioorganic Chemistry and Molecular Engineering of the Ministry of Education, Beijing National Laboratory of Molecular Sciences (BNLMS), College of Chemistry and Molecular Engineering, Peking University, 202 Chengfu Road, Beijing 100871, China Moffat et al. 2014; Schmidel et al. 2014).”
BackgroundEpigenetic assays for chemical biology and drug discovery
Gul, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0342-6 · Cited by 34
Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery
Huang, C.-T., Hsieh, C.-H., Chung, Y.-H., Oyang, Y.-J., Huang, H., & Juan, H. (2019) · iScience · doi:10.1016/j.isci.2019.04.039 · Cited by 33
“Cellular molecular responses to small-molecule treatments have provided many possibilities for cancer drug discovery (Moffat et al., 2014).”
BackgroundKrushkal, J., Negi, S., Yee, L. M., Evans, J. R., Grkovic, T., Palmisano, A., Fang, J., Sankaran, H., McShane, L. M., Zhao, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12849 · Cited by 35
BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
Fiorentino, F. P., Marchesi, I., Schröder, C., Schmidt, R., Yokota, J., & Bagella, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249595 · Cited by 32
“Therefore, we took a mixed target-based and a phenotypic approach to identify new drug combinations that, ideally, would be highly toxic in SCLC cells with limited toxicity in non-tumor cells [69,70].”
MethodTargeting tumor cells based on Phosphodiesterase 3A expression
Nazir, M., Senkowski, W., Nyberg, F., Blom, K., Edqvist, P.-H. D., Jarvius, M., Andersson, C. R., Gustafsson, M. G., Nygren, P., Larsson, R. L., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.10.032 · Cited by 34
Breakthroughs in AI and multi-omics for cancer drug discovery: A review
Fatima, I., Rehman, A., Ding, Y., Wang, P., Meng, Y., Rehman, H. U., Warraich, D. A., Wang, Z., Feng, L., & Liao, M. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116925 · Cited by 38
Evaluation of the Droplet-Microarray Platform for High-Throughput Screening of Suspension Cells
Popova, A. A., Depew, C. E., Permana, K. M., Trubitsyn, A. G., Peravali, R., Ordiano, J. Á. G., Reischl, M., & Levkin, P. A. (2016) · SLAS TECHNOLOGY · doi:10.1177/2211068216677204 · Cited by 29
“Across all therapeutic areas, 32% of drugs approved between 1999 and 2008 were discovered using phenotypebased approaches.(1) Phenotypic screenings are also used as an in vitro model for toxicity tests and for studies of druginduced liver injury (DILI).”
BackgroundCarvalho, R. F., do Canto, L. M., Cury, S. S., Hansen, T. F., Jensen, L. H., & Rogatto, S. R. (2021) · Cancers · doi:10.3390/cancers13215492 · Cited by 32
“Unfortunately, the discovery and translation of new drugs for cancer treatment is costly [2], requires years of research and development [3,4], and only a few drugs entering clinical trials are eventually approved for clinical use [5,6].”
BackgroundPooled genetic screens with image‐based profiling
Walton, R. T., Singh, A. K., & Blainey, P. C. (2022) · Molecular Systems Biology · doi:10.15252/msb.202110768 · Cited by 31
“…relying on cytotoxicity readouts have generally returned the same “low-hanging fruit” — previously known MOAs that are highly druggable, such as microtubule dynamics and DNA modification (Moffat et al , 2014), slowing the discovery of selective therapies that address new tumor-specific MOAs.”
BackgroundVIBRANT: spectral profiling for single-cell drug responses
Liu, X., Shi, L., Zhao, Z., Shu, J., & Min, W. (2024) · Nature Methods · doi:10.1038/s41592-024-02185-x · Cited by 32
“Compared with traditional target-based approaches, the advantage of phenotypic screening is to identify drug leads that are more likely to possess thera-peutically relevant drug MoA without concerning their target-binding affinity 33 .”
Multi-targeted drug design strategies for the treatment of schizophrenia
Stępnicki, P., Kondej, M., Koszła, O., Żuk, J., & Kaczor, A. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1816962 · Cited by 36
Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline
Menshykau, D. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.019 · Cited by 27
Maltais, R., Roy, J., & Poirier, D. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00111 · Cited by 29
Discovery of novel drug targets and their functions using phenotypic screening of natural products
Chang, J., & Kwon, H. J. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-015-1681-y · Cited by 27
“Romidepsin is also known as a potent histone deacetylase inhibitor (HDACi) [48, 49].”
BackgroundKremer, L., Schultz‐Fademrecht, C., Baumann, M., Habenberger, P., Choidas, A., Klebl, B., Kordes, S., Schöler, H. R., Sterneckert, J. L., Ziegler, S., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707394 · Cited by 26
Bacterial Cytological Profiling Reveals the Mechanism of Action of Anticancer Metal Complexes
Sun, Y., Heidary, D. K., Zhang, Z., Richards, C. I., & Glazer, E. C. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00407 · Cited by 30
Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells
Pruteanu, L.-L., Kopanitsa, L., Módos, D., Kletnieks, E., Samarova, E. I., Bender, A., Gomez, L. D., & Bailey, D. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239551 · Cited by 29
“The feasibility of using gene expression as a measure of phenotypic change has been established for several systems, including the comparison of normal and glioblastoma-derived neural stem cells [64], drug screening [36] and toxicogenomics [65].”
BackgroundSelf-citationDunbar, K. J., Valančiūtė, A., de Lima, A. C. S., Freile, P., Jamieson, T. J., Rajasekaran, V., Blackmur, J. P., Ochocka-Fox, A.-M., Guazzelli, A., Cammareri, P., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.09.010 · Cited by 31
“the limited clinical success of target-based drug discovery approaches, there is an accelerated drive toward diseaserelevant phenotypic screening.(26) Several pathways dysregulated in CRC, including Wnt, converge to regulate both CSCs and EMT, highlighting pro-neoplastic phenotypes that themselves may serve as respons…”
BackgroundMetabolic engineering approaches for the biosynthesis of antibiotics
Yook, G., Nam, J., Jo, Y.-M., Yoon, H. S., & Yang, D. (2025) · Microbial Cell Factories · doi:10.1186/s12934-024-02628-2 · Cited by 27
“Phenotype screening is an exploratory process that identifies chemicals with antibiotic properties by testing the viability of pathogens when treated with candidate chemicals, based on their observable effects on biochemical activities or MoA, without prior knowledge of the targets [120, 121].”
Identification and Development of Therapeutics for COVID-19
Rando, H. M., Wellhausen, N., Ghosh, S., Lee, A. J., Dattoli, A. A., Hu, F., Byrd, J. B., Rafizadeh, D. N., Lordan, R., Qi, Y., et al. (2021) · mSystems · doi:10.1128/msystems.00233-21 · Cited by 28
“Targets of repurposed drugs are often nonspecific, meaning that the MMOA can appear to be relevant to COVID-19 without a therapeutic or prophylactic effect being observed in clinical trials.”
InfluentialEmerging machine learning approaches to phenotyping cellular motility and morphodynamics
Choi, H. J., Wang, C., Pan, X., Jang, J., Cao, M., Brazzo, J. A., Bae, Y., & Lee, K. (2021) · Physical Biology · doi:10.1088/1478-3975/abffbe · Cited by 29
Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation
Mader, M. M., Rudolph, J., Hartung, I. V., Uehling, D., Workman, P., & Zuercher, W. J. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0536 · Cited by 26
Self-citationJoining Forces: The Chemical Biology–Medicinal Chemistry Continuum
Plowright, A. T., Ottmann, C., Arkin, M. R., Auberson, Y. P., Timmerman, H., & Waldmann, H. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.019 · Cited by 28
Cheng, K., Lee, J., Hao, P., Yao, S. Q., Ding, K., & Li, Z. (2017) · Angewandte Chemie · doi:10.1002/ange.201709584 · Cited by 25
Rapid phenotyping of cancer stem cells using multichannel nanosensor arrays
Geng, Y., Goel, H. L., Le, N. D. B., Yoshii, T., Mout, R., Tonga, G. Y., Amante, J. J., Mercurio, A. M., & Rotello, V. M. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.05.009 · Cited by 25
Byrne, F. L., Olzomer, E. M., Marriott, G. R., Quek, L., Katen, A., Su, J., Nelson, M. E., Hart‐Smith, G., Larance, M., Sebesfi, V. F., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101374 · Cited by 24
Liao, W., Yang, W., Zhang, Y., FanHong, Z., 徐杰诚, Yan, Z., Mingxin, P., Xu, X., Zhou, S., Zeng, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.658197 · Cited by 27
“When it comes to drug screening for drug discovery and development, enormous amounts of money and time must be spent to obtain clinically approved drugs (Moffat et al., 2014).”
BackgroundTau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma
Hedna, R., Kovacic, H., Pagano, A., Peyrot, V., Robin, M., Devred, F., & Breuzard, G. (2022) · Cancers · doi:10.3390/cancers14215386 · Cited by 28
Guo, C., Chang, Y., Wang, X., Zhang, C., Hao, P., Ding, K., & Li, Z. (2018) · Chemical Communications · doi:10.1039/c8cc08685k · Cited by 25
Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
Potdar, S., Ianevski, F., Ianevski, A., Tanoli, Z., Wennerberg, K., Seashore-Ludlow, B. A., Kallioniemi, O., Östling, P., Aittokallio, T. A., & Saarela, J. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad390 · Cited by 28
Innovating cancer drug discovery with refined phenotypic screens
Wang, Z., Hulíková, A., & Swietach, P. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.06.001 · Cited by 25
CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes
Roth, A., Gihring, A., Bischof, J., Pan, L., Oswald, F., & Knippschild, U. (2022) · Cancers · doi:10.3390/cancers14051345 · Cited by 27
Synthesis and identification of unprecedented selective inhibitors of CK1ε
Silveira‐Dorta, G., Sousa, I. J., Fernandes, M. X., Martı́n, V. S., & Padrón, J. M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.046 · Cited by 23
Newman, D. J., Cragg, G. M. L., & Kingston, D. G. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00005-5 · Cited by 35
Small-Molecule Screening for Genetic Diseases
Markossian, S., Ang, K. K. H., Wilson, C. G. M., & Arkin, M. R. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021452 · Cited by 26
Zulkipli, N. N., Rahman, S. A., Taib, W. R. W., Razali, R. M., Ismail, I., Ahmad, W. A. N. W., & Dahlan-Daud, C. K. (2024) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-024-00490-0 · Cited by 24
“…to target-based biochemical assays, phenotypic assays not only yield a greater number of first-of-its-kind small-molecule pharmaceuticals [96], but they also effectively identify small molecules with thera - peutic effects that are pertinent to their specific molecular mechanisms of action [97].”
BackgroundIdentification of protein binding partners of small molecules using label-free methods
Saxena, C. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1227316 · Cited by 24
He, Y., Zheng, M., Li, Q., Hu, Z., Zhu, H., Liu, J., Wang, J., Xue, Y., Li, H., & Zhang, Y. (2017) · Organic Chemistry Frontiers · doi:10.1039/c6qo00847j · Cited by 22
Modeling the tumor immune microenvironment for drug discovery using 3D culture
Lee, J. Y., & Chaudhuri, O. (2021) · APL Bioengineering · doi:10.1063/5.0030693 · Cited by 24
Wenzel, C., Otto, S., Prechtl, S., Parczyk, K., & Steigemann, P. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.10.003 · Cited by 26
Zhong, C., Zhu, R., Jiang, T., Tian, S., Zhao, X., Wan, X., Jiang, S., Chen, Z., Gong, R., He, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202305035 · Cited by 24
In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach
Ciallella, J. R., & Reaume, A. G. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.04.001 · Cited by 24
Luo, Y., Zeng, R., Guo, Q., Xu, J., Sun, X., & Wang, L. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob02193g · Cited by 21
Rodriguez, K. X., Howe, E. N., Bacher, E. P., Burnette, M. D., Meloche, J. L., Meisel, J. E., Schnepp, P. M., Tan, X., Chang, M., Zartman, J. J., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900266 · Cited by 21
Han, H., Sun, X., Guo, X., Wen, J., Zhao, X., & Zhou, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1552741 · Cited by 28
“In recent years, phenotype-based drug screening methods have gradually emerged and combined with advances in robotics and imaging technologies to realize multi-parameter analysis and improve screening quality (Moffat et al., 2014).”
Dai, Z., An, L.-Y., Chen, X.-Y., Yang, F., Zhao, N., Li, C., Ren, R., Li, B., Tao, W., Li, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02210 · Cited by 20
Zhang, W., Qi, L., Liu, Z., He, S., Wang, C., Wu, Y., Han, L., Liu, Z., Fu, Z., Tu, C., et al. (2023) · MedComm · doi:10.1002/mco2.317 · Cited by 23
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
Morris, J., Kunkel, M. W., White, S. L., Wishka, D. G., Lopez, O. D., Bowles, L., Brady, P. S., Ramsey, P., Grams, J., Rohrer, T. N., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0267 · Cited by 22
In silicotools used for compound selection during target-based drug discovery and development
Caldwell, G. W. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1043885 · Cited by 25
“The phenotypic-based approaches involve screening a collection of compounds in animal or cellular models where the target is unknown and using phenotypic changes in these systems as the criteria to select hits [104-107].”
BackgroundLai, F., Shen, Z., Wen, H., Chen, J., Zhang, X., Lin, P., Yin, D., Cui, H., & Chen, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.169 · Cited by 20
Metadata
- Authors
- Moffat, J. G., Rudolph, J., & Bailey, D.
- Affiliations
- Genentech (US)
- Corresponding author
- Moffat, John G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-07-18
- Volume
- 13
- Issue
- 8
- Pages
- 588-602
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2123059506
- Semantic Scholar
- 1042a4c884176fac046b7c6751c953ed949f8066
- Cited by
- 507
- References
- 182
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 43 · 2023: 30 · 2022: 36 · 2021: 48 · 2020: 45 · 2019: 48 · 2018: 52 · 2017: 56 · 2016: 42 · 2015: 39 · 2014: 3
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- phenotypic screening, anticancer drug discovery, anticancer drug development, small molecule anticancer agents, FDA-approved anticancer drugs, target-based drug discovery, cytotoxicity, mitotic arrest
- MeSH terms
- Antineoplastic Agents, Drug Screening Assays, Antitumor, Forecasting, Humans, Neoplasms, Phenotype, History, 20th Century, History, 21st Century, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.